Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A New Blood Biomarker of Acute Stroke
Cerebrovascular Disease and Interventional Neurology
(-)
102
Authors/Disclosures
Halim Abboud No disclosure on file
Ahmed Negida, MD, PhD (Virginia Commonwealth University) Dr. Negida has nothing to disclose.
No disclosure on file
No disclosure on file
Elena Meseguer No disclosure on file
Phillippa Lavallee No disclosure on file
Olivier Simon No disclosure on file
Jean-Marc Olivot No disclosure on file
Mikael Mazighi (Hospital Bichat Claude Bernard) No disclosure on file
No disclosure on file
No disclosure on file
Pierre Amarenco, MD Dr. Amarenco has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AstraZeneca. Dr. Amarenco has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Amarenco has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for BMS. The institution of Dr. Amarenco has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Pfizer. Dr. Amarenco has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for KOWA company.
Patricia Musolino, MD, PhD An immediate family member of Dr. Musolino has received personal compensation for serving as an employee of EMD Sorono. Dr. Musolino has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Minoryx Pharmaceuticals. Dr. Musolino has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for IONIS Pharmaceuticals . Dr. Musolino has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Inozyme Pharma. Dr. Musolino has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Vertex Pharmaceuticals. An immediate family member of Dr. Musolino has or had stock in 2seventy Bio. An immediate family member of Dr. Musolino has or had stock in Editas Medicine. An immediate family member of Dr. Musolino has or had stock in Generation Bio. An immediate family member of Dr. Musolino has or had stock in Beam Therapeutics. An immediate family member of Dr. Musolino has or had stock in Ebotec . An immediate family member of Dr. Musolino has or had stock in Novonordisk. An immediate family member of Dr. Musolino has or had stock in Morphosys. The institution of Dr. Musolino has received research support from National Institute of Health-NINDS-R01. The institution of Dr. Musolino has received research support from Angea Biotherapeutics. The institution of Dr. Musolino has received research support from Minoryx Pharmaceuticals. The institution of Dr. Musolino has received research support from Belanger Foundation. The institution of Dr. Musolino has received research support from Rozwat Family Foundation. The institution of Dr. Musolino has received research support from Dooley Family Foundation. Dr. Musolino has received intellectual property interests from a discovery or technology relating to health care. Dr. Musolino has received publishing royalties from a publication relating to health care.